For combination products, device IP can supplement IP covering the drug molecule to add significant further protection. As combination products evolve to operate in a more patient-centered ecosystem, blending drugs, devices, and services to improve patient outcomes, device IP not only encompasses traditional delivery, diagnostic, & monitoring devices, but is also evolving to include hardware, software, and data mining. But complexity, development, and ownership issues make it challenging to secure strategic patent protection to cover this broad range of technologies. This panel will discuss how device IP may add value to your combination product, and how to build such a portfolio.